FENNEC PHARMACEUTICALS

Fennec Pharmaceuticals is a biopharmaceutical company focused on the development of its primary product candidate, Sodium Thiosulfate (STS), for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Co. has licensed from Oregon Health & Science University intellectual property rights for the use of STS as a chemoprotectant, and is developing STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children.
  • TickerFRX_CN
  • ISINCA31447P1009
  • ExchangeToronto Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryCanada
 PRESS RELEASE
FRX_CN FENNEC PHARMACE... (Health Care)

Fennec Announces Results of Annual Meeting

Fennec Announces Results of Annual Meeting RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in Irvine, California and online on June 29, 2021. Detailed results of the vote for the election of directors are set out below: Name of NomineeVotes For% Votes ForVotes Withheld% Votes W...

David Nierengarten
  • David Nierengarten
 PRESS RELEASE
FRX_CN FENNEC PHARMACE... (Health Care)

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Applicatio...

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™ ~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ NDA Resubmission for PEDMARK for the Prevention of Cisplatin-Induced Ototoxicity for Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ RESEARCH TRIANGLE PARK, N.C., June 22, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
FRX_CN FENNEC PHARMACE... (Health Care)

Fennec Announces Results of Annual Meeting

Fennec Announces Results of Annual Meeting RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in Irvine, California and online on June 29, 2021. Detailed results of the vote for the election of directors are set out below: Name of NomineeVotes For% Votes ForVotes Withheld% Votes W...

David Nierengarten
  • David Nierengarten
 PRESS RELEASE
FRX_CN FENNEC PHARMACE... (Health Care)

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Applicatio...

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™ ~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ NDA Resubmission for PEDMARK for the Prevention of Cisplatin-Induced Ototoxicity for Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ RESEARCH TRIANGLE PARK, N.C., June 22, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
FRX_CN FENNEC PHARMACE... (Health Care)

Fennec Announces Results of Annual Meeting

Fennec Announces Results of Annual Meeting RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in Irvine, California and online on June 29, 2021. Detailed results of the vote for the election of directors are set out below: Name of NomineeVotes For% Votes ForVotes Withheld% Votes W...

David Nierengarten
  • David Nierengarten
 PRESS RELEASE
FRX_CN FENNEC PHARMACE... (Health Care)

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Applicatio...

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™ ~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ NDA Resubmission for PEDMARK for the Prevention of Cisplatin-Induced Ototoxicity for Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ RESEARCH TRIANGLE PARK, N.C., June 22, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
FRX_CN FENNEC PHARMACE... (Health Care)

Fennec Announces Results of Annual Meeting

Fennec Announces Results of Annual Meeting RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in Irvine, California and online on June 29, 2021. Detailed results of the vote for the election of directors are set out below: Name of NomineeVotes For% Votes ForVotes Withheld% Votes W...

David Nierengarten
  • David Nierengarten
 PRESS RELEASE
FRX_CN FENNEC PHARMACE... (Health Care)

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Applicatio...

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™ ~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ NDA Resubmission for PEDMARK for the Prevention of Cisplatin-Induced Ototoxicity for Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ RESEARCH TRIANGLE PARK, N.C., June 22, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus

ResearchPool Subscriptions

Get the most out of your insights

Get in touch